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Alzheimer’s disease (AD) and neocortical Lewy body disease (LBD) are the most common 
neurodegenerative dementias, with no available curative treatment. Elucidating pathomechanism and 
identifying novel therapeutic targets are of paramount importance. Lemur tyrosine kinase 2 (LMTK2) 
is involved in several physiological and pathological cellular processes. Herewith a neuropathological 
characterization is presented in AD and neocortical LBD samples using chromogenic and fluorescent 
LMTK2 immunohistochemistry on post-mortem brain tissues and compared them to age-matched 
controls (CNTs). LMTK2 immunopositivity was limited to the neuronal cytoplasm. Neurons, including 
tau-positive tangle-bearing ones, showed decreased chromogenic and immunofluorescent labelling in 
AD in every cortical layer compared to CNT and neocortical LBD. Digital image analysis was performed 
to measure the average immunopositivity of groups. Mean grey values were calculated for each 
group after measuring the grey scale LMTK2 signal intensity of each individual neuron. There was 
significant difference between the mean grey values of CNT vs. AD and neocortical LBD vs. AD. The 
moderate decrease in neocortical LBD suggests the effect of coexisting AD pathology. We provide 
neuropathological evidence on decreased neuronal LMTK2 immunolabelling in AD, with implications for 
pathogenesis.
Dementias are challenging health issues in our aging society. Alzheimer’s disease (AD) and neocortical Lewy 
body disease (LBD) are the most common causes of dementia accounting for 75–80 percent of the cases1. In 
order to develop more efficient disease-modifying treatments, the molecular, biochemical and genetic alterations 
(‘omics’) should be better explored2–4. Neuropathological hallmarks of AD are the deposition of extracellular 
β-amyloid plaques and intracellularly aggregated neurofibrillary tangles (NFTs)5. Although, neocortical LBD is 
an α-synucleinopathy characterized by the pathological aggregation and intracellular deposition of α-synuclein 
forming Lewy bodies and Lewy neurites, coexisting AD-type NFT pathology is also frequently observed. The 
major component of NFT is hyperphosphorylated microtubule-associated protein tau. Tau is involved in a myriad 
of physiological cellular functions such as stabilization of microtubules, axonal transport, synaptic transmission 
or activation of unfolded protein response6–9. Under pathological circumstances the hyperphosphorylated tau10 
is prone to self-aggregation and toxic through sequestering normal tau and other microtubule associated proteins 
resulting in microtubule disassembly11. NFT burden inversely correlates with the number of surviving neurons, 
suggesting that neurofibrillary lesions have key role in degenerative changes and apoptotic cell loss12. Despite the 
crucial role of tau hyperphosphorylation in the pathogenesis the initiative event leading to pathological activ-
ity of numerous kinases remains to be elucidated. Cyclin-dependent kinase 5 (CDK5) and Glycogen synthase 
kinase-3β (GSK3β) are two major tau-kinases. Moreover, CDK5 can suppress the activity of GSK3β indirectly, but 
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the precise mechanism behind this observation was unknown until Manser et al. identified the Lemur tyrosine 
kinase 2 (LMTK2) as the missing link of the signalling pathway between the two above mentioned tau-kinases13. 
LMTK2 is a member of the membrane-anchored protein kinase family14. It has important interacting partners 
such as CDK5/p35 complex, catalytic subunit of Protein Phosphatase 1 (PP1C), cystic fibrosis transmembrane 
conductance regulator (CFTR) and myosin VI. Owing to the large LMTK2 interactome it is not surprising that 
the protein is implicated in several vital physiological functions and diseases (Table 1) including AD15. However, 
human neuropathological studies are not yet available. To fill this gap, in this study chromogenic and fluores-
cent immunohistochemical (IHC) characterization of LMTK2 was performed on human AD and neocortical 
LBD brain samples. Digital image analysis was applied to measure the average immunolabelling of experimental 
groups.
Materials and Methods
All procedures were conducted under the ethical approval of the Institutional Ethics Committee of the MRC 
London Neurodegenerative Diseases Brain Bank (18/WA/0206) at the Institute of Psychiatry Psychology and 
Neuroscience, King’s College London and the Brains for Dementia Research (BDR) Project (08/H0704/128 + 5). 
Informed consent for autopsy, neuropathological assessment and research participation were obtained from all 
subjects and data was anonymised. Block taking for histological and immunohistochemical studies and neuro-
pathological assessment for neurodegenerative diseases was carried out in accordance with standard criteria.
Three experimental groups were established. The observed brain region was the middle frontal gyrus 
(Brodmann area 9). In the disease groups we selected 6–6 AD and neocortical LBD cases with severe neurode-
generative changes (Braak stage VI and diffuse neocortical, respectively). In these cases dementia was diagnosed 
in life and confirmed by neuropathology, while in the control (CNT) group there were 6 samples of aged-matched 
patients (died of non-neurological causes), without significant neurodegenerative changes. There were 11 females 
and 7 males similarly distributed in the experimental groups. All patients were older than 60-year-old, the average 
post-mortem delays were 38 (±11.8 SEM) hours for AD, 47.1 (±8.6 SEM) hours for CNT and 43.3 (±7.8 SEM) 
hours for neocortical LBD cases (Supplementary Table S1).
Chromogenic immunohistochemistry (CHR-IHC). 7µm-thick formalin-fixed paraffin-embedded 
(FFPE) sections were routinely de-waxed in decreasing alcohol concentrations (2 × 5 mins. xylene, 5 mins. 
absolute alcohol, 5 mins. 96% (v/v) alcohol, 5 mins. 80% (v/v) alcohol, 5 mins. 70% (v/v) alcohol), blocked for 
endogenic peroxidase activity in methanol containing 3% (v/v) H2O2, and heat-treated in Tris(hydroxymethyl)
aminomethane - Ethylenediaminetetraacetic acid (TRIS-EDTA; 10 mM TRIS Base, 1 mM EDTA, pH = 9.0) 
antigen retrieval buffer solutions using a microwave oven (5 mins. 800 watt, 2 × 5 mins. 250 watt). Non-specific 
antibody binding sites were blocked with 20 mMol TRIS buffered saline (Sigma-Aldrich, TRIS Buffered Saline 
20 × solution, 20 mMol Tris, pH = 7.4) containing 10% (v/v) normal goat serum (Agilent/Dako). Sections were 
incubated with the primary LMTK2 antibody (KPI-2, clone H-9, SantaCruz Biotechnology) at 4 °C overnight. On 
the following day samples were incubated for an hour at room temperature with goat anti-mouse biotinylated sec-
ondary antibody (Agilent/Dako). Immunohistochemical detection was performed with VECTASTAIN® Elite® 
ABC HRP Kit (Vector laboratories) – prepared and used according to the manufacturer’s protocol. Chromogen 
substrate 3,3′-diaminobenzidine tetrahydrochloride (DAB) reagent (Sigma-Aldrich 10 mg tablets) was applied 
for 4 minutes, then nuclear staining was carried out with Harris’ haematoxylin (30 seconds). Sections were 
dehydrated in increasing alcohol concentrations (5 mins. 70% (v/v) alcohol, 5 mins. 80% (v/v) alcohol, 5 mins. 
96% (v/v) alcohol, 5 mins. absolute alcohol, 5 mins. xylene), then mounted and coverslipped using ClearVue™ 
Coverslipper (Thermo Fisher Scientific). Dilutions for primary and secondary antibodies were 1:50 and 1:200, 
respectively in 20 mMol TRIS buffered saline. Working solution for rinsing after certain steps (antigen retrieval, 
primary and secondary antibodies, ABC kit) was 20 mMol TRIS buffered saline. For quality control purposes 
IHC ‘negative’ slides without application of primary antibody were also made.
Immunofluorescent immunohistochemistry (IF-IHC). Several steps overlap with the above detailed 
CHR-IHC protocol (de-wax, antigen retrieval, primary antibody), while others are unnecessary for IF-IHC 
reaction (endogenous peroxidase blocking, biotinylated secondary antibody, chromogen substrate). The work-
ing solution was phosphate buffered saline (Biocare Medical, PBS Plus 10x solution, pH = 7.3). Sections were 
incubated with fluorescent-dye conjugated secondary antibody (Goat Anti-Mouse IgG H&L - Alexa Fluor® 
594, Abcam) for an hour at room temperature. Dilution for secondary antibody was 1:200 in working solution. 
Vector® TrueVIEW™ Autofluorescence Quenching Kit (Vector laboratories) was used to remove non-specific 
autofluorescence. Coverslipping and nuclear staining were carried out manually using Vectashield® Antifade 
Mounting Medium with DAPI (4′,6-diamidino-2-phenylindole; Vector laboratories).
Physiological processes Pathological conditions
Neuronal differentiation65 Prostate cancer57–60,66
Intracellular vesicle trafficking21 Lung cancer61,63
Axonal transport13 Cystic fibrosis20,67
Spermatogenesis68 Neurodegeneration15
Table 1. Implications of Lemur tyrosine kinase 2 (LMTK2) in physiological and pathological processes.
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Assessement of CHR-IHC. Slides were scanned with Virtual Slide Microscope VS120 (Olympus Corp.) 
with the same illumination intensities, exposure times, and camera settings. Cell-specificity, subcellular localisa-
tion and association of LMTK2 with disease-specific pathological changes (β-amyloid plaques and NFTs) were 
evaluated by neuropathologist (TH).
Digital analysis for IF-IHC. Immunofluorescent microscopy was performed with an Axio Imager Z2 micro-
scope equipped with 20×/0,5 420350–9900 EC Plan-Neofluar objective, Coolcube 1 m S/N: 003274. 60N-C 1″ 
1,0×. 426114 camera and appropriate filter sets (Carl Zeiss AG). For digital analysis we used Isis fluorescence 
imaging platform (MetaSystems Hard & Software GmbH). 5 photos/cases were taken randomly at medium mag-
nification (20×) with the same illumination intensities, exposure times, and camera settings. Data processing was 
carried out with ImageJ software. Images (90 pcs) were opened in one stack to guarantee that the applied modifi-
cations are performed on every single image at the same time with the same settings. After setting the threshold 
to 1–255 an erode function was executed on the binary images to filter the edges of neurons. The ‘Analyse parti-
cles’ module measured the mean greyscale values of the identified objects. To ensure that every assessed particle 
was neuron, different filters were used: 1) automatic selection based on the size; 2) subsequent manual selection 
applied to each particle to remove objects which were identified by the software and were not neurons (e.g. blood 
vessels). The mean greyscale intensities were determined for each case by summarizing the results of individual 
cells. Then mean grey intensities for CNT, AD and neocortical LBD groups were also calculated.
Statistical analysis. For statistical analysis of grey intensities of fluorescent IHC signals SigmaPlot 12.0 
software (Systat Software Inc.) was used. Shapiro-Wilk normality test, equal variance test, one-way analysis of 
variance (ANOVA) and all pairwise comparison (Holm-Sidak method) were performed to determine statistical 
significance of the results. Moreover, analysis of covariance (ANCOVA) was also run in order to evaluate the 
effects of age at death or post-mortem delay on the results. Testing was carried out with SPSS 25 software (IBM 
Corp.) dependent variables were IF-IHC results, fixed factors were disease and gender and covariates were age at 
death and post-mortem delay.
Results
Immunohistochemistry showed strong neuron-specific cytoplasmic reaction; glial cells and nuclei of neurons 
were negative (Fig. 1). In AD the extracellular β-amyloid plaques did not display positive reaction (Fig. 2. Panel 
A). The average LMTK2 immunopositivity was similarly weak in both tangle-bearing neurons and morphologi-
cally normal cells. However, NFTs showed slightly stronger reaction (Fig. 2. Panel B). The difference between the 
immunopositivity of the experimental groups was perceptible to the naked eye (Fig. 3). Basically, the LMTK2 
immunoreaction in AD was weaker compared to CNT and neocortical LBD. This tendency was detectable in 
every cortical layer (Supplementary Fig. S1). Number of analysed neurons were 1272 on fluorescent images. 
Figure 4 depicts the summarized mean grey intensities of CNT, AD and neocortical LBD groups. Although the 
mean intensity values of individual cases vary in the experimental groups (ranged between 13.6–19, 10.8–13.4 
and 12.8–16.4 in CNT, AD and neocortical LBD, respectively), their standard deviations tend to be almost iden-
tical providing adequate basis for statistical analysis. One-way ANOVA showed statistically significant difference 
among the mean grey intensities of CNT, AD and neocortical LBD groups with fluorescent (p < 0,001) IHC. All 
pairwise comparison revealed statistically significant alteration between CNT-AD (p < 0.001) and neocortical 
LBD-AD (p = 0.014) groups (Fig. 4). There was no significant result in the case of CNT versus (vs) neocortical 
LBD comparison. According to ANCOVA test neither the age at death (p = 0.100), nor the post-mortem delay 
(p = 0.718) influenced significantly the results of IF-IHC.
Figure 1. Neuron-specificity of lemur tyrosine kinase 2 (LMTK2) in human brain tissue. The figure depicts 
the border (dashed line) between grey (on the left) and white (on the right) matter. Neurons show cytoplasmic 
immunopositivity (Insert A), while in the glial cells positive reaction is not detectable (Insert B). [The protein 
was visualized by 3,3′-Diaminobenzidine (DAB) chromogen. Nuclear counterstain was haematoxylin. Scale bar: 
100 µm].
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Discussion
In accordance with the literature we found that in neural tissue LMTK2 expression was localized to the cytoplasm 
of neurons, while nuclei and glial cells were negative16. β-amyloid plaques in AD did not cumulate LMTK2 pro-
posing that it is not involved in the formation of these protein aggregates. Interestingly, in AD tangle-bearing 
neurons and morphologically normal cells showed similarly weak average cytoplasmic immunoreaction suggest-
ing that LMTK2 reduction is a general feature in the NFT-affected brain regions. This alteration is probably an 
early event of the pathogenesis which precedes and predicts the appearance of morphological changes. Contrarily, 
NFTs themselves displayed slightly stronger LMTK2 positivity. It could be explained by the followings: on the 
one hand LMTK2 may be a currently undescribed constituent of NFTs and on the other hand NFT as a con-
dense protein aggregate may cumulate LMTK2 even though the average cytoplasmic expression of the enzyme is 
relatively low in tangle-bearing neurons. In order to evaluate the immunofluorescent LMTK2 immunoreaction 
we used a slightly modified, adapted version of a previously described ImageJ software-based method17. In our 
study we demonstrated decreased LMTK2 immunopositivity in AD samples compared to neocortical LBD and 
age-matched CNT. Statistical tests showed significant difference between the mean grey intensities of CNT-AD 
and neocortical LBD-AD groups, while in the case of CNT- neocortical LBD comparison, in spite of the decreased 
immunopositivity in LBD, the results were not statistically significant. The moderately reduced average immu-
nopositivity in neocortical LBD compared to CNT may resulted from the frequent coexistence of a AD-type 
pathology18. This observation is suggesting that decreased LMTK2 expression is probably an AD- (or tauopathy-) 
specific alteration and it may not associate directly to α-synucleinopathies. In accordance with our results a recent 
genome-wide gene-expression study has detected decreasing LMTK2 expression during disease progression in 
the cortical and hippocampal regions of a transgenic tau (Tau P301L) mouse model [43]. Furthermore, in a com-
plementary work Morotz et al. have recently found reduced LMTK2 levels in human AD samples by western blot 
analysis19. Since they investigated many of our patients’ frozen tissue samples, their study validates our results. 
However, they could not provide neither morphological nor LBD analysis. Consequently, our study provides the 
first neuropathological characterization of LMTK2 in post-mortem human AD and neocortical LBD tissue.
Although the analysis of LMTK2 signalling is out of the scope of this current work, based on recent cell 
biological and animal model studies reduced LMTK2 level alters three important cellular mechanisms which 
may contribute to neurodegeneration: (i) axonal transport, (ii) tau hyperphosphorylation, (iii) apoptosis15 
(Supplementary Fig. S2).
Disrupted axonal transport. As polarized cells, neurons require harmonized axonal transport to supply 
their dendrites and axon(s) with essential macromolecules produced by the soma. Under physiological conditions 
LMTK2 is involved in the coordination of intracellular molecular trafficking20,21. However, any defect of this 
well-organized machinery may result in the pathological accumulation of intracellular organelles and proteins. 
It is known that disrupted axonal transport is an early event in the pathogenesis of several neurodegenerative 
diseases22. A recent paper has described an LMTK2-mediated pathway in connection with a Kinesin-1-associated 
axonal transport13. As a major motor protein Kinesin-1 plays a crucial role in the axonal transport of subcellu-
lar organelles, intracellular vesicles and signalling proteins23–25. The protein has two heavy chains moving along 
microtubules, and two light chains – responsible for cargo binding. Phosphorylation of Kinesin-1 light chains 
Figure 2. Association between lemur tyrosine kinase 2 (LMKT2) and Alzheimer’s disease (AD)-specific 
pathological changes. Panel (A) There is no LMTK2 immunoreaction in β-amyloid plaque (black star). Panel 
(B) The average LMTK2 immunopositivity is similarly weak in tangle-bearing (on the left) and morphologically 
normal (on the right) neurons . However, neurofibrillary tangles show slightly stronger reaction (black 
arrow). [The protein was visualized by 3,3′-Diaminobenzidine (DAB) chromogen. Nuclear counterstain  with 
haematoxylin. Scale bar: 20 µm].
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(KLCs) is a crucial regulatory mechanism23. GSK3β can transfer phosphoryl groups to KLC2 directly, result-
ing in cargo release and repressed Kinesin-1- dependent transport26–28. Manser and co-workers have recently 
described how CDK5 influences this signalling pathway via LMTK2-PP1C interaction27,29 CDK5/p35 complex 
Figure 3. Decreased labelling of lemur tyrosine kinase 2 (LMTK2) in Alzheimer’s disease (AD) as compared 
to neocortical Lewy body disease (LBD) and control brains. In the control and neocortical LBD the LMTK2 
immunopositivity is more intense with chromogenic (brown)(Panels A,B) and fluorescent (red) technique 
(Panels E,F), respectively, compared to AD (Panels C,G). IHC negative slides (without application of primary 
anti-LMTK2 antibody) are also presented (Panels D,H). [The protein was visualized by 3,3′-Diaminobenzidine 
(DAB) chromogen and Alexa Fluor® 594 fluorescent dye. Nuclear counterstains were haematoxylin and 
4′,6-diamidino-2-phenylindole (DAPI) on chromogenic and fluorescent slides, respectively. Scale bar: 50 µm].
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as an upstream activator of LMTK2 phosphorylates it on serine-1418. In this case LMTK2 can phosphorylate 
the catalytic subunit of PP1 leading to decreased activity of the phosphatase enzyme. Finally, these steps contrib-
ute to increased inhibitory phosphorylation on GSK3β serine-9. Since, supressed GSK3β is not able to inhibit 
KLC2 this signalling pathway supports cargo binding to the subunit13,29. One of the macromolecules trans-
ported by Kinesin-1 is mothers against decapentaplegic homolog 2 (Smad2)13,30. Smad2 is an essential member 
of transforming growth factor-β (TGF-β) nucleocytoplasmic signalling pathway31. siRNA- induced silencing of 
LMTK2 disrupts Kinesin-1- mediated axonal transport of Smad2, that in turn inhibits TGF-β nuclear signalling32. 
Disorganised TGF-β/Smad2 pathway has been reported in Alzheimer’s disease32,33. These findings conclude that 
reduced LMTK2 level may alter physiological axonal transport, thereby contribute to neurodegeneration.
Tau hyperphosphorylation. Tau hyperphosphorylation is a pathological hallmark of AD34. Role of CDK5 
and GSK3β in this process was investigated in several studies35–38. Physiologically, CDK5 is activated by the cofac-
tor p3539. Under neuronal stress increased calpain activation results in cleavage of p35 producing p25 and p1040,41. 
CDK5/p25 complex has prolonged half-life/activity leading to hyperphosphorylation of downstream targets (e.g. 
tau)38,42–44. As we previously described CKD5/p35 can attenuate GSK3β indirectly via LMTK2- mediated path-
way. However, in the lack of LMTK2 signalling PP1 can remove inhibitory phosphoryl groups from GSK3β13,29. 
Enhanced GSK3β activity is highly implicated in the hyperphosphorylation of tau protein35. We suppose that in 
AD the aberrant coupling of upstream regulator CDK5 with p25 and further currently unknown mechanisms 
contribute to decreased activity and expression of LMTK2 which leads to overactivation of GSK3β and ultimately 
to the formation of hyperphosphorylated tau and NFTs.
Apoptosis. Conti et al. have recently characterized a potential LMTK2- mediated pathway in the reg-
ulation of apoptosis45. In their study siRNA- induced LMTK2 silencing reduced the levels of antiapoptotic 
B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra-large (Bcl-xL), and elevated the level of proapoptotic 
Bcl-2-interacting mediator of cell death (Bim). These cells showed increased sensitivity to tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) and certain chemotherapeutic agents. Altered Bim and Bcl-2 
levels resulted from the missing LMTK2- induced inhibition on PP1C and GSK3β45. Furthermore, increased 
Bim expression has been also observed in AD brain samples, while elevated Bcl-2 level seems to be protective 
against AD-related cell stressors46,47. Group of researchers consider neurodegeneration as the ‘cancer of neu-
rons’48–50. Although neurons lost their proliferative capacity, certain harmful stimuli (e.g. excessive oxidative 
stress, β-amyloid accumulation, etc.) can induce aberrant cell cycle re-entry51–55. However, this abnormal process 
is terminated by different pro-apoptotic mechanisms54,56. Presumably, noxious stimuli which trigger uncontrolled 
proliferation and cancer formation in other tissues could result in extensive neuronal death in the central nervous 
system. Role of LMTK2 has been discussed in several malignant tumours. Decreased LMTK2 expression was 
observed in prostate adenocarcinoma as well as in other common malignancies such as lung or skin cancers57–63. 
Since, LMTK2 is involved in the sophisticated regulation of apoptotic factors we could consider it as a tumour 
suppressor protein. Therefore, downregulation of LMTK2 may contribute to both tumourigenesis and neurode-
generation via dysregulation of neuronal homeostasis.
Strengths of study include providing the first histopathological characterization of LMTK2 in the two most 
frequent human neurodegenerative dementias. We have described LMTK2’s cell specificity, intracellular localisa-
tion, cortical distribution and association with the hallmark neurodegenerative changes (tangle-bearing neurons, 
Figure 4. Fluorescent lemur tyrosine kinase 2 (LMTK2) immunohistochemistry (IHC) intensity plots of 
control (CNT), Alzheimer’s disease (AD) and neocortical Lewy body disease (LBD) groups. The mean grey 
intensities of the fluorescent signals are presented. There are statistically significant differences between 
CNT-AD (p < 0.001(***)) and neocortical LBD- AD (p < 0.05 (*)), while the comparison between CNT 
and neocortical LBD groups does not show significant result. [Color code: yellow columns = CNT; blue 
columns = AD, grey columns = LBD].
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β-amyloid plaques). We have demonstrated that LMTK2 immunopositivity does not change remarkably in neo-
cortical LBD compared to CNT patients. In addition, we validated the results of complementary proteomic and 
cell biological studies confirming that the protein’s level is significantly decreased in AD. The used IF-IHC  is an 
easily accessible, relatively cheap and fast technique compared to quantitative molecular biological methods (i.e. 
western blot, qPCR) which are not feasible in the first-line pathological workup.
Limitations of the study: In the current work we have not performed further quantitave analysis (i.e. western 
blot, qPCR). However, in a complementary work Morotz et al. validated the decreased LMTK2 expression on 
partially the same CNT and AD cases with western blot analysis19. Finally, although the number of cases (n = 6/
groups) are relatively low, the tendency of immunopositivity within the experimental groups (without notable 
outliers), the significant difference among AD, neocortical LBD and CNT groups, the large number of analysed 
neurons and the complementary western blot data further strongly support our findings.
Conclusion and Prospects
This study provides the first neuropathological characterization of LMTK2 in human AD and neocortical LBD 
samples. Besides the previously undescribed morphological features, we have detected significantly decreased 
LMTK2 immunopositivity in AD compared to CNT or neocortical LBD groups. According to our results LMTK2 
reduction is specific to AD (or tauopathies), while the moderately decreased immunoreaction in LBD compared 
to CNT was probably caused by the frequently coexisting AD-type pathology. These are consistent with evidences 
from cell biological and animal model studies. LMTK2 may contribute to neurodegeneration in AD via three 
mechanisms: disrupted axonal transport, tau hyperphosphorylation, and enhanced apoptosis. Since available 
treatments in AD are symptomatic with a limited efficacy, there is a need for discovering novel therapeutic targets. 
A recent study has identified a 2-O-Tetradecanoylphorbol-13-acetate (TPA) responsive element in the promoter 
of LMTK2 gene. Stimulation of this region by the synthetic Protein Kinase C activator TPA increased the expres-
sion of LMTK264 which is theoretically beneficial in AD. However, further investigations are required to elucidate 
LMTK2’s role in neurodegeneration and as a therapeutic target in AD.
Data availability
The datasets used and/or analysed during the current study available from the corresponding author on 
reasonable request.
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